Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa

Conditions:   Retinitis Pigmentosa;   Retinitis Pigmentosa Syndrome Intervention:   Drug: EA-2353 Sponsor:   Endogena Therapeutics, Inc Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials